Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.

Pubmed ID: 29284111

Pubmed Central ID: PMC7643562

Journal: The American journal of medicine

Publication Date: June 1, 2018

Link: https://ac.els-cdn.com/S0002934317312925/1-s2.0-S0002934317312925-main.pdf?_tid=2ced6824-4049-4924-b49b-b8fbe65edc74&acdnat=1528975961_fb509fcfc776d73b6eec9591e01c11c0&link_time=2024-12-01_15:02:11.776213

MeSH Terms: Humans, Male, Female, Aged, Risk Factors, Middle Aged, Heart Failure, Hospitalization, Treatment Outcome, Cardiotonic Agents, Digoxin

Grants: U01 NS086294, 1IP2PI000722-01

Authors: Kent DM, Konstam MA, Upshaw JN, van Klaveren D

Cite As: Upshaw JN, van Klaveren D, Konstam MA, Kent DM. Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. Am J Med 2018 Jun;131(6):676-683.e2. Epub 2017 Dec 25.

Studies:

Abstract

BACKGROUND: Digoxin has been shown to reduce heart failure hospitalizations with a neutral effect on mortality. It is unknown whether there is heterogeneity of treatment effect for digitalis therapy according to predicted risk of heart failure hospitalization. METHODS AND RESULTS: We conducted a post hoc analysis of the Digitalis Investigator Group (DIG) studies, randomized controlled trials of digoxin vs placebo in participants with heart failure and left ventricular ejection fraction ≤45% (main DIG study, n = 6800) or >45% (ancillary DIG study, n = 988). Using a previously derived multistate model to risk-stratify DIG study participants, we determined the differential treatment effect on hospitalization and mortality outcomes. There was a 13% absolute reduction in the risk of any heart failure hospitalizations (39% vs 52%; odds ratio 0.58; 95% confidence interval 0.47-0.71) in the digoxin vs placebo arms in the highest-risk quartile, compared with a 3% absolute risk reduction for any heart failure hospitalization (17% vs 20%; odds ratio 0.84; 95% confidence interval, 0.66-1.08) in the lowest-risk quartile. There were 12 fewer total all-cause hospitalizations per 100 person-years in the highest-risk quartile compared with an increase of 8 hospitalizations per 100 person-years in the lowest-risk quartile. There was neutral effect of digoxin on mortality in all risk quartiles and no interaction between baseline risk and the effect of digoxin on mortality (P = .94). CONCLUSIONS: Participants in the DIG study at higher risk of hospitalization as identified by a multistate model were considerably more likely to benefit from digoxin therapy to reduce heart failure hospitalization.